Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: High level expression in clear cell carcinoma

被引:38
作者
Adley, Brian P. [2 ]
Gleason, Kara J. [3 ]
Yang, Ximing J. [4 ]
Stack, M. Sharon [1 ]
机构
[1] Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO 65212 USA
[2] Advocate Lutheran Gen Hosp, Park Ridge, IL USA
[3] Northwestern Univ, Feinberg Med Sch, Dept Cell & Mol Biol, Chicago, IL 60611 USA
[4] Northwestern Univ, Feinberg Med Sch, Dept Pathol, Chicago, IL 60611 USA
基金
美国国家卫生研究院;
关键词
Ovarian clear cell carcinoma; Matrix metalloprotease (MMP); MMP-14; MMP-2; Invasion; Metastasis; GENE-EXPRESSION; 1-MATRIX METALLOPROTEINASE; CLINICAL CHARACTERISTICS; EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; PROGNOSTIC VALUE; MESSENGER-RNA; I COLLAGEN; INVASION; MT1-MMP;
D O I
10.1016/j.ygyno.2008.09.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Clear cell carcinomas of the ovary constitute approximately 5% of all ovarian neoplasms and have a distinct gene expression profile relative to other ovarian carcinoma histotypes. Tumors often present as an early stage large pelvic mass with a high degree of recurrence and frequent early metastasis. Matrix metalloproteinases (MMPs) play a role in intraperitoneal metastasis through breakdown of cell-cell and cell-matrix barriers, enabling anchoring of secondary lesions and promoting proliferation in a geometrically constrained matrix environment. The objective of this study was to evaluate MMP expression in ovarian clear cell carcinoma. Methods. Immunohistochemistry was used to evaluate expression of membrane type 1 MMP (MMP-14), MMP-2 and MMP-9 in a panel of ovarian tumors. Western blotting and gelatin zymography were used to examine MMP-14 expression and activity in the clear cell carcinoma cell line ES2. The ability of ES2 cells to invade and proliferate within three-dimensional collagen gels was evaluated. Results. High level expression of MMP-14 and MMP-2 were observed in ovarian clear cell carcinoma relative to other histotypes (94-95% strong positive). MMP-14 was expressed and active in cultured ES2 cells. ES2 cells also exhibited MMP-dependent invasion of and proliferation within three-dimensional collagen gels. Conclusions. The high level expression of MMP-14 together with in vitro functional analyses suggest that MMP-14 may contribute to both the proliferative capacity and the enhanced parenchymal metastasis of ovarian clear cell carcinoma. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:319 / 324
页数:6
相关论文
共 43 条
[1]   MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: Possible implications for the role of desmoplastic fibroblasts [J].
Afzal, S ;
Lalani, EN ;
Poulsom, R ;
Stubbs, A ;
Rowlinson, G ;
Sato, H ;
Seiki, M ;
Stamp, GWH .
HUMAN PATHOLOGY, 1998, 29 (02) :155-165
[2]   Membrane type 1-matrix metalloproteinase: Substrate diversity in pericellular proteolysis [J].
Barbolina, Maria V. ;
Stack, M. Sharon .
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2008, 19 (01) :24-33
[3]   Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression [J].
Barbolina, Maria V. ;
Adley, Brian P. ;
Ariztia, Edgardo V. ;
Liu, Yueying ;
Stack, M. Sharon .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (07) :4924-4931
[4]   Clinical characteristics of clear cell carcinoma of the ovary [J].
Behbakht, K ;
Randall, TC ;
Benjamin, I ;
Morgan, MA ;
King, S ;
Rubin, SC .
GYNECOLOGIC ONCOLOGY, 1998, 70 (02) :255-258
[5]   Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary [J].
Crotzer, David R. ;
Sun, Charlotte C. ;
Coleman, Robert L. ;
Wolf, Judith K. ;
Levenback, Charles F. ;
Gershenson, David M. .
GYNECOLOGIC ONCOLOGY, 2007, 105 (02) :404-408
[6]   The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma [J].
Davidson, B ;
Goldberg, I ;
Gotlieb, WH ;
Kopolovic, J ;
Ben-Baruch, G ;
Nesland, JM ;
Reich, R .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2002, 187 (1-2) :39-45
[7]  
Davidson B, 2001, AM J CLIN PATHOL, V115, P517
[8]  
DeFrias D V S, 2002, Cancer Treat Res, V107, P185
[9]  
DeNictolis M, 1996, INT J GYNECOL PATHOL, V15, P102
[10]  
Ellerbroek SM, 1999, CANCER RES, V59, P1635